TY - JOUR
T1 - Corrigendum to ‘Current Use and Trends in Hematopoietic Cell Transplantation in the United States’ [Transplantation and Cellular Therapy 26/8 (2020) e177-e182]
AU - D'Souza, Anita
AU - Fretham, Caitrin
AU - Lee, Stephanie J.
AU - Arora, Mukta
AU - Brunner, Janet
AU - Chhabra, Saurabh
AU - Devine, Steven
AU - Eapen, Mary
AU - Hamadani, Mehdi
AU - Hari, Parameswaran
AU - Pasquini, Marcelo C.
AU - Perez, Waleska
AU - Phelan, Rachel A.
AU - Riches, Marcie L.
AU - Rizzo, J. Douglas
AU - Saber, Wael
AU - Shaw, Bronwen E.
AU - Spellman, Stephen R.
AU - Steinert, Patricia
AU - Weisdorf, Daniel J.
AU - Horowitz, Mary M.
N1 - Publisher Copyright:
© 2021 The American Society for Transplantation and Cellular Therapy
PY - 2021/3/1
Y1 - 2021/3/1
N2 - The authors regret an error in the original paper wherein the number of patients with Diffuse Large B Cell Lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation in the U.S. in 2018 was incorrectly reported. Prior to 2018, the majority of DLBCL were collected under the category ‘NHL diffuse, large B-cell. To align data reporting with 2016 World Health Organization classification of lymphoid neoplasms, in 2018, the CIBMTR forms added new categories (including, DLBCL – germinal center B-cell type, DLBCL – activated B-cell type, and NHL with c-myc and bcl-2 and/or bcl6 rearrangements). We erroneously did not include these newly added subsets of DLBCL, resulting in the appearance of fewer patients undergoing autologous hematopoietic cell transplantation for DLBCL in 2018. Upon identification of this error, we have created an updated Figure 3. The authors would like to apologise for any inconvenience caused.
AB - The authors regret an error in the original paper wherein the number of patients with Diffuse Large B Cell Lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation in the U.S. in 2018 was incorrectly reported. Prior to 2018, the majority of DLBCL were collected under the category ‘NHL diffuse, large B-cell. To align data reporting with 2016 World Health Organization classification of lymphoid neoplasms, in 2018, the CIBMTR forms added new categories (including, DLBCL – germinal center B-cell type, DLBCL – activated B-cell type, and NHL with c-myc and bcl-2 and/or bcl6 rearrangements). We erroneously did not include these newly added subsets of DLBCL, resulting in the appearance of fewer patients undergoing autologous hematopoietic cell transplantation for DLBCL in 2018. Upon identification of this error, we have created an updated Figure 3. The authors would like to apologise for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85108559179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108559179&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2021.02.006
DO - 10.1016/j.jtct.2021.02.006
M3 - Comment/debate
C2 - 36202526
AN - SCOPUS:85108559179
SN - 2666-6367
VL - 28
SP - 715
EP - 716
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 10
ER -
